Branded Generics Market Set to Surge to 410.86 Billion by 2032, Reflecting a 5.60% CAGR Growth | PMR

𝐀𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐛𝐫𝐚𝐧𝐝𝐞𝐝 𝐠𝐞𝐧𝐞𝐫𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟐𝟓𝟐.𝟒𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟒𝟏𝟎.𝟖𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟔𝟎% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.

The rising prevalence of chronic conditions such as diabetes, cancer, and cardiovascular diseases is one of the major trends shaping the market trajectory. The Branded Generics Market report by Polaris Market Research offers a thorough analysis of the market. All the major industry aspects, including market share, size, growth trends, recent development, and segmental overview, have been covered to help businesses make highly informed decisions.

𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
https://www.polarismarketresearch.com/industry-analysis/branded-generics-market/request-for-sample

𝐓𝐡𝐞 𝐊𝐞𝐲 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐈𝐧 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐫𝐞 𝐆𝐢𝐯𝐞𝐧 𝐁𝐞𝐥𝐨𝐰:

• Teva Pharmaceutical
• Lupin
• Sanofi
• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Endo International
• GlaxoSmithKline
• Pfizer
• Apotex
• Viatris Inc

𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

• 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞: The global market for branded generics was valued at USD 252.46 billion in 2023 and is expected to grow to USD 410.86 billion by 2032.

• 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐚𝐭𝐞: The industry is projected to grow at a CAGR of 5.60 % during the forecast period from 2024 to 2032.

• 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐂𝐨𝐯𝐞𝐫𝐞𝐝:The market is primarily segmented based on drug class, application, route of administration, distribution channel, and region.

• 𝐑𝐞𝐠𝐢𝐨𝐧𝐬 𝐈𝐧𝐜𝐥𝐮𝐝𝐞𝐝:The study covers all the major market regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

𝐆𝐞𝐭 𝐀𝐡𝐞𝐚𝐝 𝐰𝐢𝐭𝐡 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/buy/2509/2

𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧

When a new medicine is introduced in the market, it is patented and sold under a specific brand name. After the expiration of the medicine's patent, other firms may sell generic versions of the medicine. These generic versions slightly differ from the branded version, but tend to have the same efficacy. Generic alternatives are typically cheaper than their branded-name counterparts.

This is because companies that manufacture these drugs don't need to make heavy investments in developing and marketing them. Branded generics are available for numerous drug classes, including Alkylating agents, antimetabolites, hormones, anti-hypertensive, anti-depressants, and anti-psychotics, amongst others.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬

High ANDA approvals and the introduction of generic products are major factors supporting branded generics market growth. Besides, governments worldwide are promoting the use of generic drugs to lower healthcare costs and enhance access to affordable healthcare. The government initiatives to promote generic products are also impacting the industry demand favorably.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤:

𝐁𝐲 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬
• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptics

𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧
• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Gastrointestinal Diseases
• Dermatological Diseases
• Acute and Chronic Pain

𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥
• Topical
• Oral
• Parenteral
• Others

𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:

𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭: Branded generics play a crucial role in the management of chronic diseases such as hypertension, diabetes, and cardiovascular conditions, providing affordable treatment options for long-term use.

𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: Branded generics contribute significantly to the treatment of infectious diseases, including antibiotics for bacterial infections and antivirals for viral illnesses, addressing public health needs globally.

𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬:Branded generics offer affordable alternatives for cancer treatments, including chemotherapy drugs and supportive medications, improving access to essential oncology therapies.

𝐌𝐞𝐧𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐌𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: Branded generics in the mental health sector provide cost-effective options for treating conditions such as depression, anxiety, and bipolar disorder, enhancing access to psychiatric care.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
https://www.polarismarketresearch.com/industry-analysis/branded-generics-market

𝐁𝐫𝐚𝐧𝐝𝐞𝐝 𝐆𝐞𝐧𝐞𝐫𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• Anti-hypersensitive segment accounted for the largest share, owing to rise in cardiac ailments among geriatrics, and availability of low-cost alternatives

• Oral segment accounted for the larger market share, owing to the advantages of oral based drug administration with minimal nursing experience, with high accept patient acceptability

• Retail pharmacy is projected to experience larger revenue share, primarily due to increase in number of retail pharmacies in the developed markets

• APAC is projected to register a higher growth rate in the study period, due to increase in preference of low-cost medicines

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market

𝐇𝐞𝐚𝐫𝐢𝐧𝐠 𝐀𝐢𝐝𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-hearing-aids-market

𝐅𝐚𝐜𝐢𝐚𝐥 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-facial-injectable-market

𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐞𝐯𝐢𝐜𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-diabetes-device-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:
Polaris Market Research
Phone: +1-929-297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally.

This release was published on openPR.